Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Biologics Market – Insights

A biologic drug (biologics) is a product that is produced from living organisms or contain components of living organisms. New technologies and novel therapies are emerging for manufacturing of new biologics, which holds a prominent future for the global biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases such as cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.

The global biologics market is estimated to be valued at US$ 255.19 Billion in 2019 and is expected to exhibit a CAGR of 7.6% over the forecast period (2019-2027).

Global Biologics Market Share (%) Analysis, By Drug Class, 2019

Biologics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing robust pipeline of biologics is expected to drive growth of the global biologics market.

Key players in the market have number of biopharmaceuticals products, which are in clinical trials and are expected to receive approval in the near future. Thus, robust pipeline of biopharmaceutical products is expected to significantly drive growth of global biologics market over the forecast period.  For instance, Amgen Inc. has monoclonal antibody AMG 820 and AMG 966 in phase I clinical trials, monoclonal antibody AMG 301, AMG 557, AMG 714, and Tezepelumab, in phase II clinical trials; and monoclonal antibody Aimovig (erenumab), EVENTIYTM (romosozumab), Tezepelumab, and Prolia (denosumab) in phase III clinical trials.

Moreover, Novartis International AG, a Switzerland-based pharmaceutical company has number of monoclonal antibodies in pipeline. The company has monoclonal antibody Xolair, Cosentyx, OMB157, RTH258, and Lucentis in phase III clinical trial; monoclonal antibodies QGE031 and BYM338 in phase II clinical trials.

Global Biologics Market – Restraints

However, middle-to-low income economies such as India, Indonesia, Bangladesh, Mexico, Brazil, and certain European countries have inadequate availability of biologics due to high cost and lack of reimbursement for biologics. Therefore, lower availability and affordability of biologics in middle and lower income countries are expected to hamper the biologics market growth over the forecast period.  For instance, according to article ‘Affordability Issues of Biotech Drugs in Low- and Middle-Income Countries (LMICs)’ published in Drug Designing and Intellectual Properties International Journal 2019, in India alone, as many as 63 million people are forced into poverty every year, owing to very high health expenses, the majority of which, are out-of-pocket payments for medicines.

Global Biologics Market - Regional Insights

On the basis of region, the global biologics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America is expected to hold a dominant position in the global biologics market over the forecast period, owing to rising number of approvals of biologics drugs by the regulatory authorities. For instance, in 2017, the U.S. FDA approved GlaxoSmithKline’s biologic Nucala for the treatment of a rare disease called eosinophilic granulomatosis with polyangiitis (EPGA)

Asia Pacific is expected to be the fastest growing region in the global biologics market, owing to increasing prevalence of diabetes in this region. For instance, according to the International Diabetes Federation (IDF) Diabetes Atlas: 2017, number of people with diabetes aged between 20 to 79 years in South East Asia region and Western Pacific region in 2017 was 82 million and 159 million, respectively

Global Biologics Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Biologics  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2020)

Global Biologics Market - Competitive Landscape

Key players operating in the global biologics market include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.

Biological products include wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for the treatment of genetic disorders. Biologics are also used to treat children with CLN2 disease, which is a form of Batten disease. Moreover, in 2017, BioMarin Pharmaceutical Inc. received the U.S. FDA approval for its Brineura (cerliponase alfa), which is indicated for the treatment CLN2 disease.

Market Dynamics

In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologics market. For instance, in 2017, Amgen Inc. received the U.S. Food and Drug Administration (FDA) for its Blincyto (Blinatumomab) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

Furthermore, in 2017, Janssen Biotech, Inc. received the U.S FDA approval for Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma.

However, high cost of biologics for the treatment of diseases such as rheumatoid arthritis, cancer, multiple sclerosis, psoriasis, and other diseases is expected to hamper biologics market growth over the forecast period. For instance, according to the data published in NCBI in 2018, the cost of biologics for treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases can range from US$ 10,000 to US$ 30,000 per year in the U.S. and can exceed US$ 500,000 per year for the most expensive biologics.

Furthermore, it is more difficult to manufacture biologics than chemical drugs, as they are extremely sensitive due to its very complex molecules.

Key features of the study:

  • This report provides in-depth analysis of the global biologics market, market size (US$ Bn), and compound annual growth rate (CAGR (%) for the forecast period, 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global biologics market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global biologics market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Global Biologics Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Biologics Market, by Drug Class:
    • Monoclonal Antibody
    • Vaccine
    • Recombinant Insulin
    • Human Growth Hormone
    • Blood Factor
    • Fusion Protein
    • Erythropoietin
    • Recombinant Enzyme
    • Interferon
    • Colony-stimulating Factor
    • Cell Therapy
    • Gene Therapy
    • Oligonucleotides
    • Others
  • Global Biologics Market, By Therapeutic Application:
    • Oncology
    • Metabolic Disorders
    • Autoimmune/Immunologic Diseases
    • Ophthalmic Diseases
    • Inflammatory Bowel Diseases (IBDs)
    • Respiratory Disorders
    • Neurological Disorders
    • Musculoskeletal Disorders (MSDs)
    • Cardiovascular Diseases (CVDs)
    • Infectious Diseases
    • Others
  • Global Biologics Market, by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Biologics Market, by Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Monoclonal Antibody
        • Vaccine
        • Recombinant Insulin
        • Human Growth Hormone
        • Blood Factor
        • Fusion Protein
        • Erythropoietin
        • Recombinant Enzyme
        • Interferon
        • Colony-stimulating Factor
        • Gene Therapy
        • Cell Therapy
        • Oligonucleotides
        • Others
      • By Therapeutic Application:
        • Oncology
        • Metabolic Disorders
        • Autoimmune/Immunologic Diseases
        • Ophthalmic Diseases
        • Inflammatory Bowel Diseases (IBDs)
        • Respiratory Disorders
        • Neurological Disorders
        • Musculoskeletal Disorders (MSDs)
        • Cardiovascular Diseases (CVDs)
        • Infectious Diseases
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Monoclonal Antibody
        • Vaccine
        • Recombinant Insulin
        • Human Growth Hormone
        • Blood Factor
        • Fusion Protein
        • Erythropoietin
        • Recombinant Enzyme
        • Interferon
        • Colony-stimulating Factor
        • Gene Therapy
        • Cell Therapy
        • Oligonucleotides
        • Others
      • By Therapeutic Application:
        • Oncology
        • Metabolic Disorders
        • Autoimmune/Immunologic Diseases
        • Ophthalmic Diseases
        • Inflammatory Bowel Diseases (IBDs)
        • Respiratory Disorders
        • Neurological Disorders
        • Musculoskeletal Disorders (MSDs)
        • Cardiovascular Diseases (CVDs)
        • Infectious Diseases
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Monoclonal Antibody
        • Vaccine
        • Recombinant Insulin
        • Human Growth Hormone
        • Blood Factor
        • Fusion Protein
        • Erythropoietin
        • Recombinant Enzyme
        • Interferon
        • Colony-stimulating Factor
        • Gene Therapy
        • Cell Therapy
        • Oligonucleotides
        • Others
      • By Therapeutic Application:
        • Oncology
        • Metabolic Disorders
        • Autoimmune/Immunologic Diseases
        • Ophthalmic Diseases
        • Inflammatory Bowel Diseases (IBDs)
        • Respiratory Disorders
        • Neurological Disorders
        • Musculoskeletal Disorders (MSDs)
        • Cardiovascular Diseases (CVDs)
        • Infectious Diseases
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Monoclonal Antibody
        • Vaccine
        • Recombinant Insulin
        • Human Growth Hormone
        • Blood Factor
        • Fusion Protein
        • Erythropoietin
        • Recombinant Enzyme
        • Interferon
        • Colony-stimulating Factor
        • Gene Therapy
        • Cell Therapy
        • Oligonucleotides
        • Others
      • By Therapeutic Application:
        • Oncology
        • Metabolic Disorders
        • Autoimmune/Immunologic Diseases
        • Ophthalmic Diseases
        • Inflammatory Bowel Diseases (IBDs)
        • Respiratory Disorders
        • Neurological Disorders
        • Musculoskeletal Disorders (MSDs)
        • Cardiovascular Diseases (CVDs)
        • Infectious Diseases
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Monoclonal Antibody
        • Vaccine
        • Recombinant Insulin
        • Human Growth Hormone
        • Blood Factor
        • Fusion Protein
        • Erythropoietin
        • Recombinant Enzyme
        • Interferon
        • Colony-stimulating Factor
        • Gene Therapy
        • Cell Therapy
        • Oligonucleotides
        • Others
      • By Therapeutic Application:
        • Oncology
        • Metabolic Disorders
        • Autoimmune/Immunologic Diseases
        • Ophthalmic Diseases
        • Inflammatory Bowel Diseases (IBDs)
        • Respiratory Disorders
        • Neurological Disorders
        • Musculoskeletal Disorders (MSDs)
        • Cardiovascular Diseases (CVDs)
        • Infectious Diseases
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Monoclonal Antibody
        • Vaccine
        • Recombinant Insulin
        • Human Growth Hormone
        • Blood Factor
        • Fusion Protein
        • Erythropoietin
        • Recombinant Enzyme
        • Interferon
        • Colony-stimulating Factor
        • Gene Therapy
        • Cell Therapy
        • Oligonucleotides
        • Others
      • By Therapeutic Application:
        • Oncology
        • Metabolic Disorders
        • Autoimmune/Immunologic Diseases
        • Ophthalmic Diseases
        • Inflammatory Bowel Diseases (IBDs)
        • Respiratory Disorders
        • Neurological Disorders
        • Musculoskeletal Disorders (MSDs)
        • Cardiovascular Diseases (CVDs)
        • Infectious Diseases
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Bristol-Myers Squibb Company (BMS) *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Merck & Co., Inc.
    • Roche AG
    • Merck KGaA
    • AstraZeneca Plc
    • Regeneron Pharmaceuticals, Inc
    • Novartis International AG
    • Pfizer, Inc.
    • Amgen, Inc.
    • AbbVie, Inc.
    • Sanofi S.A.
    • Eli Lilly & Company
    • Novo Nordisk A/S
    • Johnson & Johnson
    • GlaxoSmithKline Plc
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen S.A.
    • Allergan Plc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Therapeutic Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Biologics & Biosimilars Overview
    • Impact Analysis
    • Patent Expiry Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • Product Approval/Launch
    • Collaboration-Acquisition
    • Market Trends
    • PEST Analysis
    • Epidemiology
  4. Global Biologics Market, By Drug Class, 2019 – 2027, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Monoclonal Antibody
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Vaccine
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Recombinant Insulin
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Human Growth Hormone
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Blood Factor
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Fusion Protein
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Erythropoietin
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Interferon
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Recombinant Enzyme
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Colony-stimulating Factor
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Cell Therapy
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Gene Therapy
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Oligonucleotides
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Others (Peptide, Botulinum Toxin, and Others)
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
  5. Global Biologics Market, By Therapeutic Application, 2019 – 2027, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Metabolic Disorders
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Autoimmune/Immunologic Diseases
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Ophthalmic Diseases
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Inflammatory Bowel Diseases (IBDs)
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Respiratory Disorders
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Neurological Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Musculoskeletal Disorders (MSDs)
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Cardiovascular Diseases (CVDs)
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Infectious Diseases
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Others
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
  6. Global Biologics Market, By Distribution Channel, 2019 – 2027, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Retail Pharmacies
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
    • Online Pharmacies
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Billion)
  7. Global Biologics Market, By Region, 2019 – 2027 (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Billion)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Billion)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Billion)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Billion)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Billion)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Billion)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Billion)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Bristol-Myers Squibb Company (BMS)
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Regeneron Pharmaceuticals, Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AbbVie, Inc.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Eli Lilly & Company
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novo Nordisk A/S
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Johnson & Johnson
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ipsen S.A.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Allergan Plc.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 49 figures on "Biologics Market” - Global forecast to 2027”

Frequently Asked Questions

Biologics Market can expand at 7.6% CAGR from 2019 to 2027
The North America can dominate the global biologics market due to rising number of regulatory approvals and launches of biologics
• By Drug Class • By Therapeutics Application • By Distribution Channel • By Region
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner